• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    MARPAI, INC. REPORTS THIRD QUARTER 2023 RESULTS

    11/13/23 4:01:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    • Continued year over year growth related to our acquisition of Maestro Health
    • Further identification and implementation of synergies and opportunities continue as a result of the acquisition
    • Veteran industry executive leadership announced along with the addition of a seasoned health care leader to strengthen the Board of Directors
    • Focus on acceleration of operating efficiencies and customer growth

    NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (NASDAQ:MRAI), an independent national Third-Party Administrator (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans, today reported financial results for the third quarter ended September 30, 2023.

    The Company's consolidated results of operations include the results of operations of Marpai and its wholly owned subsidiaries, Marpai Health, Inc. and Marpai Administrators, LLC (formerly Continental Benefits, LLC) for all periods presented, and the results of Maestro Health, LLC  ("Maestro Health") since its acquisition on November 1, 2022.

    Third Quarter 2023 Highlights:

    • Total revenue for the three months ended September 30, 2023 was $8.7 million, representing an increase of $3.8 million, or nearly 77%, over the same period in 2022. The primary reason for this increase was due to the revenue from the acquisition of Maestro Health.
    • The addition of Maestro Health, and organic sales closed by Marpai Administrators, drove a nearly 126% increase in the number of our customers' employees. As of the end of the third quarter of 2023, the total was approximately 37,000 compared to the same period last year of approximately 16,000.
    • The Company had an operating loss of approximately $7.0 million for the three months ended September 30, 2023, compared to an operating loss of approximately $5.8 million during the same period in 2022, as the Company continued to focus on closing the gap to profitability.
    • Net loss was nearly $7.3 million for the three months ended September 30, 2023, compared to net loss of approximately $5.8 million for the three months ended September 30, 2022.
    • Net loss per share for the three months ended September 30, 2023 was ($0.98) compared to ($1.14) per share from the same period last year.

    "I believe that our third quarter results reflect continued momentum towards sustainable profitability," said Marpai's new CEO Damien Lamendola. "The pace of improvement achieved and the continued cash burn rate with the volatility of the capital markets drove us to make some rapid changes which we look forward to discussing in our upcoming investors presentation."

    Other Highlights:

    Withdrawal of Registration Statement on Form S-1

    The Company has withdrawn its Form S-1 Registration Statement due to adverse market conditions. The Company is currently evaluating its financing opportunities.

    Suspending Financial Guidance

    The Company is suspending further financial guidance for full-year 2023 operating results and will not be providing specific financial guidance moving forward.

    Webcast and Conference Call Information

    Marpai will  host an Investor call and webcast on Wednesday, November 29, 2023 at 8:00 a.m. EST to introduce the new Executive Team members and to provide an overview of the Company's strategic vision and initiatives in place.  Please refer to our Investor Relations website at: https://ir.marpaihealth.com for updates and details.

    About Marpai, Inc.

    Marpai, Inc. (NASDAQ:MRAI) is a leading, national TPA (Third Party Administrator) company bringing value oriented health plan services  to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release.

    Forward-Looking Statement Disclaimer

    This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses its belief that the third quarter results reflect continued momentum towards sustainable profitability. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

    More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEET

    (in thousands,, except share and per share data)

    (UNAUDITED)







    September 30, 2023



    December 31, 2022





    (Unaudited)





    ASSETS:









    Current assets:









    Cash and cash equivalents



    $                    3,018



    $                       13,764

    Restricted cash



    11,234



    9,353

    Accounts receivable, net of allowance for credit  

    losses of $23,458 and $23,458



    977



    1,438

    Unbilled receivable



    595



    350

    Prepaid expenses and other current assets



    961



    1,602

    Other receivables



    32



    31

    Total current assets



    16,817



    26,538











    Property and equipment, net



    663



    1,506

    Capitalized software, net



    2,743



    4,589

    Operating lease right-of-use assets



    2,520



    3,842

    Goodwill



    6,035



    5,837

    Intangible assets, net



    5,502



    6,323

    Security deposits



    1,309



    1,293

    Other long-term asset



    22



    22

    Total assets



    $                  35,611



    $                       49,950

    LIABILITIES AND STOCKHOLDERS'  (DEFICIT) EQUITY









    Current liabilities:









    Accounts payable



    $                    3,101



    $                         1,458

    Accrued expenses



    4,660



    5,275

    Accrued fiduciary obligations



    9,878



    9,024

    Deferred revenue



    1,261



    289

    Current portion of operating lease liabilities



    600



    1,311

    Other short-term liabilities



    947



    —

    Due to related party



    —



    3

    Total current liabilities



    20,447



    17,360











    Other long-term liabilities



    19,113



    20,203

    Operating lease liabilities, net of current portion



    3,813



    4,772

    Deferred tax liabilities



    1,480



    1,480

    Total liabilities



    44,853



    43,815

    COMMITMENTS AND CONTINGENCIES









    STOCKHOLDERS' (DEFICIT) EQUITY









    Common stock, $0.0001 par value, 227,791,050

    shares authorized; 7,810,625 and 5,319,758 issued and

    outstanding at September 30, 2023 and December 31,

    2022, respectively (1)



    1



    1

    Additional paid-in capital



    62,476



    54,128

    Accumulated deficit



    (71,719)



    (47,993)

    Total stockholders' (deficit) equity



    (9,242)



    6,135

    Total liabilities and stockholders' (deficit) equity



    $                  35,611



    $                       49,950













    (1)  Reflects 1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

    (in thousands, except share and per share data)

    (Unaudited)







    Three Months Ended





    September 30, 2023



    September 30, 2022

    Revenue



    $                  8,729



    $                        4,938

    Costs and expenses









    Cost of revenue (exclusive of depreciation and amortization

     shown separately below)



    5,691



    3,626

    General and administrative



    4,986



    2,718

    Sales and marketing



    1,842



    1,054

    Information technology



    1,269



    1,538

    Research and development



    267



    782

    Depreciation and amortization



    927



    842

    Loss on disposal of assets



    7



    —

    Facilities



    768



    193

    Total costs and expenses



    15,757



    10,753

    Operating loss



    (7,028)



    (5,815)

    Other income (expenses)









    Other income



    130



    56

    Interest expense, net



    (384)



    (3)

    Foreign exchange (loss) gain



    (14)



    (19)

    Loss before provision for income taxes



    (7,296)



    (5,781)

    Income tax expense



    —



    —

    Net loss



    $               (7,296)



    $                     (5,781)

    Net loss per share, basic & fully diluted (1)



    $                 (0.98)



    $                       (1.14)

    Weighted average common shares outstanding, basic and

       diluted (1)



    7,479,401



    5,087,164



    (1)  Reflects 1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

    (in thousands, except share and per share data)

    (Unaudited)









    Nine Months Ended







    September 30, 2023



    September 30, 2022

    Revenue





    $     28,448



    $     16,713

    Costs and expenses











    Cost of revenue (exclusive of depreciation and

    amortization shown separately below)





    18,530



    12,324

    General and administrative





    15,938



    7,940

    Sales and marketing





    5,494



    4,830

    Information technology





    4,775



    3,862

    Research and development





    1,291



    2,684

    Depreciation and amortization





    2,974



    2,444

    Loss on disposal of assets





    350



    60

    Facilities





    1,918



    586

    Total costs and expenses





    51,270



    34,730

    Operating loss





    (22,822)



    (18,017)

    Other income (expenses)











    Other income





    231



    95

    Interest expense, net





    (1,102)



    (7)

    Foreign exchange (loss) gain





    (32)



    (5)

    Loss before provision for income taxes





    (23,725)



    (17,934)

    Income tax expense





    —



    —

    Net loss





    $   (23,725)



    $   (17,934)

    Net loss per share, basic & fully diluted (1)





    $       (3.62)



    $       (3.58)

    Weighted average common shares outstanding, basic and

       diluted (1)





    6,552,575



    5,004,779



    (1)  Reflects 1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

     

    MARPAI, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands, except share and per share data)

    (Unaudited)







    Nine Months Ended





    September 30, 2023



    September 30, 2022

    Cash flows from operating activities:









    Net loss



    $             (23,725)



    $                   (17,934)

    Adjustments to reconcile net loss to net cash used in

    operating activities:









    Depreciation and amortization



    2,974



    2,444

    Loss on disposal of assets



    350



    60

    Share-based compensation



    1,837



    2,433

    Shares issued to vendors in exchange for services



    79



    31

    Amortization of right-of-use asset



    1,289



    517

    Gain on termination of lease



    33



    —

    Non-cash interest



    1,204



    —

    Changes in operating assets and liabilities:









    Accounts receivable and unbilled receivable



    641



    16

    Prepaid expense and other assets



    216



    377

    Other receivables



    (2)



    35

    Security deposit



    (16)



    —

    Accounts payable



    336



    (433)

    Accrued expenses



    (693)



    (436)

    Accrued fiduciary obligations



    853



    (1,642)

    Operating lease liabilities



    (1,670)



    (512)

    Due To related party



    (3)



    —

    Other liabilities



    973



    (295)

    Net cash used in operating activities



    (15,324)



    (15,339)

    Cash flows from investing activities:









    Capitalization of software development costs



    —



    (810)

    Disposal of property and equipment



    27



    —

    Purchase of property and equipment



    —



    (70)

    Net cash provided by (used in) investing activities



    27



    (880)

    Cash flows from financing activities:









    Proceeds from stock options exercises



    0



    —

    Proceeds from issuance of common stock in a public

    offering, net



    6,432



    —

    Net cash provided by financing activities



    6,432



    —











    Net decrease in cash, cash equivalents and restricted cash



    (8,865)



    (16,219)











    Cash, cash equivalents and restricted cash at beginning of

    period



    23,117



    25,934

    Cash, cash equivalents and restricted cash at end of period



    $                14,252



    $                        9,715











    Reconciliation of cash, cash equivalents, and restricted cash

    reported in the condensed consolidated balance sheet









    Cash and cash equivalents



    $                  3,018



    $                        4,748

    Restricted cash



    11,234



    4,966

    Total cash, cash equivalents and restricted cash shown in the

    condensed consolidated statement of cash flows



    $                14,252



    $                        9,714

    Supplemental disclosure of non-cash activity









    Measurement period adjustment to Goodwill



    $                        198



    $                                —













     

    (PRNewsfoto/Marpai)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/marpai-inc-reports-third-quarter-2023-results-301986492.html

    SOURCE Marpai

    Get the next $MRAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Financials

    Live finance-specific insights

    See more
    • MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      Marpai's turnaround momentum is building TAMPA, Fla., May 14, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to discuss the results on May 15, 2025. Marpai CEO Damien Lamendola commented, "Our consistent double-digit success in cutting operating expenses and improving our bottom line signals what we believe is a critical inflection point for the Company. Looking ahead to the second quarter, we are focused on completing several key initiatives, including the launch of our Health

      5/14/25 4:07:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      TAMPA, Fla., March 20, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, operates as a national Third-Party Administrator (TPA) through its subsidiaries. We're transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans. The Company will host a conference call and webcast on Thursday, March 27 at 8:30 a.m. ET to present the Company's operational and financial highlights for 2024. The Company will report its fourth quarter and full year 2024 results on Wednesday after the market close. Event: Marpai 2024 Financial Results Conference Call Date: March 27, 2025 Time

      3/20/25 8:32:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Lamendola Damien was granted 600,000 shares (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      1/29/25 4:01:10 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • New insider Intelligent Fanatics Capital Management Llc claimed ownership of 3,729,414 shares (SEC Form 3)

      3 - Marpai, Inc. (0001844392) (Issuer)

      1/2/25 9:41:02 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      Marpai's turnaround momentum is building TAMPA, Fla., May 14, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to discuss the results on May 15, 2025. Marpai CEO Damien Lamendola commented, "Our consistent double-digit success in cutting operating expenses and improving our bottom line signals what we believe is a critical inflection point for the Company. Looking ahead to the second quarter, we are focused on completing several key initiatives, including the launch of our Health

      5/14/25 4:07:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

      Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

      5/13/25 9:01:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Marpai Inc.

      10-Q - Marpai, Inc. (0001844392) (Filer)

      5/14/25 4:20:40 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      5/14/25 4:15:36 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      5/13/25 9:23:22 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    See more
    • MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

      Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

      5/13/25 9:01:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

      STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

      1/22/25 5:00:00 PM ET
      $HIT
      $MRAI
      Specialty Insurers
      Finance
      Misc Health and Biotechnology Services
      Health Care
    • George Economou Files Definitive Proxy Statement and Sends Letter to Genco Shareholders

      Highlights Urgent Need for An Independent Director Perspective to Address Genco's Persistent Underperformance and Unlock Value for Shareholders Outlines Concerns with Chairman James Dolphin's Outsized Influence in the Genco Boardroom Urges Shareholders to Vote FOR the Election of GK Investor Nominee Robert Pons on the BLUE Universal Proxy Card and WITHHOLD on Genco Board Chairman James Dolphin GK Investor LLC ("GK"), an affiliate of George Economou that is an approximately 5.3% shareholder of Genco Shipping & Trading Limited ("Genco" or the "Company") (NYSE:GNK), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connec

      4/18/24 1:07:00 PM ET
      $GNK
      $INSG
      $MRAI
      $SEAC
      Marine Transportation
      Consumer Discretionary
      Telecommunications Equipment
      Telecommunications

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      12/9/24 5:14:07 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      9/4/24 7:55:41 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      5/29/24 4:01:02 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Johnson Steve Andrew was granted 100,000 shares and bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 29% to 473,061 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:54 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Director Eitan Yaron was granted 5,000 shares and bought $124,999 worth of shares (110,619 units at $1.13), increasing direct ownership by 17% to 789,073 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:32 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care